welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million
Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.

expertly curated content related to this topic
-
Randall W. Burt, MDDr. Burt is professor emeritus at the Un...
-
Lisa Brown, MSGenetic Counselor Specializations: Fa...
-
José G. Guillem, MDDr. José G. Guillem is a colorectal sur...
-
University Hospitals Cleveland Medical CenterThe history of University Hospitals Clev...
-
Brandie Leach, MS, CGCCurrently at Collaborative Group of the ...
-
St. Mark’s Hospital/Polyposis RegistryPatient Resources: Polyposis Regist...